1st Qtrly 17-18 2nd Qtrly 17-18 3rd Qtrly 17-18 4th Qtrly 17-18 31st ANNUAL REPORT 2016-2017
1st Qtrly 16-17 2nd Qtrly 16-17 3rd Qtrly 16-17 4th Qtrly 16-17 30TH ANNUAL REPORT 2015-2016
1st Qtrly 15-16 2nd Qtrly 15-16 3rd Qtrly 15-16 4th Qtrly 15-16 29TH ANNUAL REPORT 2014-2015
1st Qtrly 14-15 2nd Qtrly 14-15 3rd Qtrly 14-15 4th Qtrly 14-15 28TH ANNUAL REPORT 2013-2014
1st Qtrly 13-14 2nd Qtrly 13-14 3rd Qtrly 13-14 4th Qtrly 13-14 27TH ANNUAL REPORT 2012-2013
1st Qtrly 12-13 2nd Qtrly 12-13 3rd Qtrly 12-13 4th Qtrly 12-13 26TH ANNUAL REPORT 2011-2012
1st Qtrly 11-12 2nd Qtrly 11-12 3rd Qtrly 11-12 4th Qtrly 11-12 25TH ANNUAL REPORT 2010-2011

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE 2013

  (Rupees in '000')
S. No. Particulars Un -audited Audited
Quarter Ended Year Ended
30.06.2013 31.03.2013 30.06.2012 31.03.2013
PART - I          
1 (a) Income from Operation        
    Gross Sales 20,712 17,481 23,253 76,818
    Less: Excise Duty 1,398 1,280 1,547 5,282
      Net Sales 19,314 16,201 21,706 71,536
  (b) Other Operating  Income  - - - 323
  Total Income from Operation 19,314 16,201 21,706 71,859
2 Expenditure - - - -
  (a) Consumption of Materials
6,601
3,152
5,984
21,402
  (b) Purchase of Goods Traded
1,777
1,144
1,870
5,460
  (c) (Increase)/Decrease in stock in trade
15
2,434
2,389
1,702
  (d) Staff Cost
6,212
5,566
6,881
25,748
  (e) Depreciation
655
659
653
2,619
  (f) Other Expenditure
3,397
2,556
3,112
12,083
  Total Expenditure
18,657
15,511
20,889
69,014
3 Profit /Loss from Operation Before Other Income (1-2)
657
690
817
2,845
4 Other  Income /(Loss)
51
266
206
775
5 Profit /Loss before Interest & Exceptional items (3+4)
708
956
1,023
3,620
6 Interest
405
467
537
2,021
7 Profit /Loss  after Interest but before exceptional items (5-6)
303
489
486
1,599
8 Exceptional items  - - - -
9 Profit /Loss before Tax (7-8)
303
489
486
1,599
10 Tax Expenses (Provision for Taxation):      Current tax - - - 297
                                                                Deffered tax - - - 504
             
11 Net Profit/Loss  after Tax (9-10)
303
489
486
798
12 Paid up Equity Share Capital (Face Value 10/- Per Share) 354,35 354,35 354,35 354,35
[Net of allotment money in arrears]
13 Reserves Excluding Revaluation Reserves  - - - 8,428
14 Earning per share (EPS) before extraordinary item (not Annualised) - - - -
  Basic & Diluted - - - 0.17
             
PART-II A. PARTICULARS  OF SHAREHOLDING         
1 Public Shareholding         
  i) Number of Shares 29,04,901 29,04,901 29,04,900 29,04,901
  ii) Percentage of shareholding  63.55% 63.55% 63.55% 63.55%
2 Promoters and promoter group Shareholding         
a) Pledged/Encumbered        
i) Number of shares - - - -
  ii) Percentage of shares (as a % of the total shareholding of - - - -
  promoter and promoter group)        
  iii) Percentage of shares (as a% of the total share capital of the company) - - - -
  b) Non-encumbered        
i) Number of Shares 16,66,099 16,66,099 16,66,100 16,66,099
  ii) Percentage of shares (as a% of the total shareholding) 36.45% 36.45% 36.45% 36.45%
   of promoter and promoter group)        
  iii) Percentage of shares (as a % of the total share capital of the company) 100% 100% 100% 100%

 

  B. INVESTORS COMPLAINTS 3 Months ended 30.06.13
  Pending at Begining of the Quarter  NIL
  Received During the Quarter NIL
  Disposed of During the Quarter NIL
  Remaining at the end of the Quarter NIL

 

NOTES :-
  1. 1. The Board of Director's noted that the revenue in this quarter was less compared to the first quarter of 2012-13 due to the Strike of Wholesalers of Medicine, in Maharashtra, in the entire month of June-2013.
  2. The above financial results have been taken on record at a meeting of Board of Directors held on  31.07.2013
  3. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
  4. Previous period figures have been regrouped wherever required.

 

  For and on behalf of the Board
  COLINZ LABORATORIES LIMITED
   
Mumbai Dr. L. S. Mani
31.07.2013 Chairman & Managing Director.

                                                                                                                     

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in